Fas Ligand Protein

"Fas Ligand Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A transmembrane protein belonging to the tumor necrosis factor superfamily that was originally discovered on cells of the lymphoid-myeloid lineage, including activated T-LYMPHOCYTES and NATURAL KILLER CELLS. It plays an important role in immune homeostasis and cell-mediated toxicity by binding to the FAS RECEPTOR and triggering APOPTOSIS.

Descriptor ID	D053222
MeSH Number(s)	D12.644.276.374.750.249 D12.776.395.550.312 D12.776.467.374.750.249 D12.776.543.550.312 D23.529.374.750.249
Concept/Terms	Fas Ligand Protein Fas Ligand Protein CD95L Fas Ligand (FasL) FasL Protein TNF Superfamily, Member 6 CD178 Antigen Antigen, CD178 Antigens, CD178 Fas Ligand Tumor Necrosis Factor Ligand Superfamily Member 6 CD178 Antigens CD95 Antigen Ligand CD95 Ligand

Below are MeSH descriptors whose meaning is more general than "Fas Ligand Protein".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intercellular Signaling Peptides and Proteins [D12.644.276]
Cytokines [D12.644.276.374]
Tumor Necrosis Factors [D12.644.276.374.750]
Fas Ligand Protein [D12.644.276.374.750.249]
Proteins [D12.776]
Glycoproteins [D12.776.395]
Membrane Glycoproteins [D12.776.395.550]
Fas Ligand Protein [D12.776.395.550.312]
Intercellular Signaling Peptides and Proteins [D12.776.467]
Cytokines [D12.776.467.374]
Tumor Necrosis Factors [D12.776.467.374.750]
Fas Ligand Protein [D12.776.467.374.750.249]
Membrane Proteins [D12.776.543]
Membrane Glycoproteins [D12.776.543.550]
Fas Ligand Protein [D12.776.543.550.312]
Biological Factors [D23]
Intercellular Signaling Peptides and Proteins [D23.529]
Cytokines [D23.529.374]
Tumor Necrosis Factors [D23.529.374.750]
Fas Ligand Protein [D23.529.374.750.249]

Below are MeSH descriptors whose meaning is related to "Fas Ligand Protein".

Below are MeSH descriptors whose meaning is more specific than "Fas Ligand Protein".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Fas Ligand Protein" by people in this website by year, and whether "Fas Ligand Protein" was a major or minor topic of these publications.

Bar chart showing 13 publications over 9 distinct years, with a maximum of 4 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2002	0	1	1
2003	0	1	1
2007	1	1	2
2008	1	3	4
2009	0	1	1
2015	1	0	1
2017	1	0	1
2023	0	1	1

Below are the most recent publications written about "Fas Ligand Protein" by people in Profiles.

Mondal T, Gaur H, Wamba BEN, Michalak AG, Stout C, Watson MR, Aleixo SL, Singh A, Condello S, Faller R, Leiserowitz GS, Bhatnagar S, Tushir-Singh J. Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer. Cell Death Differ. 2023 11; 30(11):2408-2431.

View in: PubMed
S?nchez-Breta?o A, Baba K, Janjua U, Piano I, Gargini C, Tosini G. Melatonin partially protects 661W cells from H2O2-induced death by inhibiting Fas/FasL-caspase-3. Mol Vis. 2017; 23:844-852.

View in: PubMed
Shanker A, Pellom ST, Dudimah DF, Thounaojam MC, de Kluyver RL, Brooks AD, Yagita H, McVicar DW, Murphy WJ, Longo DL, Sayers TJ. Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Res. 2015 Dec 15; 75(24):5260-72.

View in: PubMed
Shanker A, Brooks AD, Jacobsen KM, Wine JW, Wiltrout RH, Yagita H, Sayers TJ. Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res. 2009 Aug 15; 69(16):6615-23.

View in: PubMed
Matarrese P, Manganelli V, Garofalo T, Tinari A, Gambardella L, Ndebele K, Khosravi-Far R, Sorice M, Esposti MD, Malorni W. Endosomal compartment contributes to the propagation of CD95/Fas-mediated signals in type II cells. Biochem J. 2008 Aug 01; 413(3):467-78.

View in: PubMed
Jia L, Yu W, Wang P, Sanders BG, Kline K. In vivo and in vitro studies of anticancer actions of alpha-TEA for human prostate cancer cells. Prostate. 2008 Jun 01; 68(8):849-60.

View in: PubMed
Jia L, Yu W, Wang P, Li J, Sanders BG, Kline K. Critical roles for JNK, c-Jun, and Fas/FasL-Signaling in vitamin E analog-induced apoptosis in human prostate cancer cells. Prostate. 2008 Mar 01; 68(4):427-41.

View in: PubMed
Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, Sayers TJ, Hudig D, Murphy WJ. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol. 2008 Jan 01; 180(1):163-70.

View in: PubMed
Armah HB, Wilson NO, Sarfo BY, Powell MD, Bond VC, Anderson W, Adjei AA, Gyasi RK, Tettey Y, Wiredu EK, Tongren JE, Udhayakumar V, Stiles JK. Cerebrospinal fluid and serum biomarkers of cerebral malaria mortality in Ghanaian children. Malar J. 2007 Nov 12; 6:147.

View in: PubMed
Boselli D, Losana G, Bernabei P, Bosisio D, Drysdale P, Kiessling R, Gaston JS, Lammas D, Casanova JL, Kumararatne DS, Novelli F. IFN-gamma regulates Fas ligand expression in human CD4+ T lymphocytes and controls their anti-mycobacterial cytotoxic functions. Eur J Immunol. 2007 Aug; 37(8):2196-204.

View in: PubMed

People

Explore

Similar Concepts

Top Journals